Alpine Immune Sciences Inc (NASDAQ:ALPN) – Investment analysts at Oppenheimer issued their FY2023 earnings per share estimates for Alpine Immune Sciences in a report released on Monday, February 11th. Oppenheimer analyst M. Breidenbach expects that the biotechnology company will post earnings of ($2.70) per share for the year. Oppenheimer has a “Buy” rating and a $13.00 price target on the stock.
ALPN has been the topic of a number of other reports. ValuEngine raised shares of Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, October 23rd. Zacks Investment Research upgraded shares of Alpine Immune Sciences from a “sell” rating to a “hold” rating in a research note on Tuesday, November 27th. Finally, $1 reaffirmed a “buy” rating and set a $13.00 price objective on shares of Alpine Immune Sciences in a research note on Tuesday. One equities research analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The stock presently has a consensus rating of “Buy” and an average target price of $12.00.
ALPN opened at $5.59 on Wednesday. Alpine Immune Sciences has a twelve month low of $3.66 and a twelve month high of $10.57. The company has a quick ratio of 9.20, a current ratio of 9.20 and a debt-to-equity ratio of 0.05. The firm has a market cap of $78.39 million, a PE ratio of -4.66 and a beta of 2.11.
In other Alpine Immune Sciences news, major shareholder Tiger Management L.L.C. sold 25,000 shares of Alpine Immune Sciences stock in a transaction dated Friday, February 8th. The stock was sold at an average price of $5.85, for a total value of $146,250.00. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, Director James N. Topper purchased 372,439 shares of the company’s stock in a transaction dated Friday, January 18th. The shares were acquired at an average price of $5.37 per share, for a total transaction of $1,999,997.43. The disclosure for this purchase can be found here. 69.00% of the stock is owned by company insiders.
A number of large investors have recently made changes to their positions in the business. Dimensional Fund Advisors LP raised its stake in shares of Alpine Immune Sciences by 122.2% during the 2nd quarter. Dimensional Fund Advisors LP now owns 32,819 shares of the biotechnology company’s stock worth $248,000 after buying an additional 18,052 shares during the period. Hikari Power Ltd purchased a new position in shares of Alpine Immune Sciences during the 4th quarter worth $453,000. Victory Capital Management Inc. grew its holdings in shares of Alpine Immune Sciences by 109.0% during the 4th quarter. Victory Capital Management Inc. now owns 136,072 shares of the biotechnology company’s stock worth $501,000 after purchasing an additional 70,980 shares during the period. Renaissance Technologies LLC lifted its stake in Alpine Immune Sciences by 20.9% during the 2nd quarter. Renaissance Technologies LLC now owns 122,424 shares of the biotechnology company’s stock worth $927,000 after acquiring an additional 21,124 shares in the last quarter. Finally, Vanguard Group Inc. lifted its stake in Alpine Immune Sciences by 5.2% during the 3rd quarter. Vanguard Group Inc. now owns 227,834 shares of the biotechnology company’s stock worth $1,442,000 after acquiring an additional 11,200 shares in the last quarter. 56.14% of the stock is owned by institutional investors.
About Alpine Immune Sciences
Alpine Immune Sciences, Inc focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer.
Featured Article: What is a good rate of return for a mutual fund?
Receive News & Ratings for Alpine Immune Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alpine Immune Sciences and related companies with MarketBeat.com's FREE daily email newsletter.